Physician profile
Randy Jacobs
NPI 1417975905
$15,937.93
in general payments reported to CMS, 2019-2025
30 companies · $1,780 in 2025
The $1,780 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,180 · 2020: $1,735 · 2021: $2,191 · 2022: $2,770 · 2023: $2,767 · 2024: $2,515 · 2025: $1,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,062.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,952.07 | 2019-2025 | |
| Leo Pharma INC. | $2,525.63 | 2019-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $1,504.60 | 2019-2025 | |
| Lilly USA, LLC | $1,442.84 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $1,337.78 | 2020-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $987.16 | 2019-2025 | Tremfya |
| Pfizer INC. | $833.02 | 2019-2025 | |
| Genzyme Corporation | $620.33 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $433.23 | 2019-2025 | Ilumya |
| Dermavant Sciences, INC. | $430.57 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $398.60 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $280.96 | 2019-2025 | Nemluvio |
| Almirall LLC | $183.13 | 2021-2023 | Klisyri |
| Amgen INC. | $166.64 | 2019-2024 | Otezla |
| Helsinn Therapeutics (U.S.), INC. | $127.98 | 2021-2025 | Valchlor |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.54 | 2022-2024 | Spevigo, Cyltezo |
| Celgene Corporation | $87.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $72.14 | 2024-2025 | Sotyktu |
| Incyte Corporation | $67.69 | 2021-2024 | Opzelura |
| Prugen, INC. Pharmaceuticals | $67.38 | 2019-2020 | |
| Genentech USA, INC. | $45.38 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $41.12 | 2023-2024 | Zoryve |
| Lnhc, INC | $38.39 | 2025 | Zelsuvmi |
| Biofrontera INC. | $33.46 | 2020 | |
| Merck Sharp & Dohme LLC | $32.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Botanix Sb INC | $20.10 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $19.96 | 2021 | |
| Organon LLC | $18.87 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $17.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.